Therapiealternativen bei amyopathischer MDA5-positiver Dermatomyositis

We report a case of an atypical course of therapy in amyopathic MDA5-antibody-positive dermatomyositis with interstitial lung disease. Due to the poor prognosis, early therapy with cyclophosphamide followed by rituximab was carried out initially in addition to the administration of prednisolone. Due...

Descripción completa

Detalles Bibliográficos
Autores principales: Schumacher, Falk, Wollsching-Strobel, Maximilian, Kroppen, Doreen, Schwarz, Sarah Bettina, Strunk, Johannes, Windisch, Wolfram, Berger, Melanie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Medizin 2023
Materias:
Kasuistiken
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10366251/
https://www.ncbi.nlm.nih.gov/pubmed/37249583
http://dx.doi.org/10.1007/s00108-023-01517-x
Descripción
Sumario:We report a case of an atypical course of therapy in amyopathic MDA5-antibody-positive dermatomyositis with interstitial lung disease. Due to the poor prognosis, early therapy with cyclophosphamide followed by rituximab was carried out initially in addition to the administration of prednisolone. Due to therapy failure, treatment was switched to mycophenolate mofetil. This showed a surprisingly rapid positive course in terms of interstitial lung disease, skin manifestation, and general disease activity.

Ejemplares similares